Literature DB >> 31196701

Identification of a novel mutation in PLA2G6 gene and phenotypic heterogeneity analysis of PLA2G6-related neurodegeneration.

Yan Ji1, Yusheng Li1, Changhe Shi1, Yuan Gao1, Jing Yang1, Dongyi Liang2, Zhihua Yang2, Yuming Xu3.   

Abstract

INTRODUCTION: This study reports a novel mutation site of the phospholipase A2 group VI (PLA2G6) gene, and analyzes the information of 67 previously published cases to elucidate PLA2G6 phenotype-genotype variations.
METHODS: We collected clinical data and examined gene mutation sites from one Chinese patient with adult-onset ataxia and her family. Next-generation sequencing (NGS) and Sanger sequencing were used to verify possible mutations. PolyPhen-2, SIFT, and MutationTaster were used to predict their pathogenicity. For analyzing the distribution frequency of the mutation, 597 healthy controls were recruited. We also analyzed the clinical and genetic information of 67 cases from 23 studies in Pubmed database.
RESULTS: A novel compound heterozygous mutation of the PLA2G6 gene, c.1648delC and c.991G > T, was found in the Chinese patient, and classified as pathogenic. The c.1648delC variation was absent in ExAC, 1000G, dbSNP databases and the 597 healthy controls. Of the 67 cases, 29 presented ataxia. The signs of cerebellar atrophy appeared in the MRIs of most patients, while signs of iron accumulation were absent in older-aged patients with a compound heterozygous mutation. Thirty-eight patients showed no ataxia. A negative or mild extrapyramidal symptom accompanied by a low age, a homogenous mutation, while moderate or severe extrapyramidal symptoms were associated with an old age and a compound heterozygous mutation.
CONCLUSION: A novel compound heterozygous mutation of the PLA2G6 gene, c.1648delC and c.991G > T, is associated with adult onset ataxia. Phenotype-genotype variations of PLA2G6 are predicted to be caused by the loss of protein or enzyme activity of phospholipase-2.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Ataxia; Heterogeneous; Phospholipase A2; Phospholipase A2 group VI gene; Phospholipase A2-associated neurodegeneration

Mesh:

Substances:

Year:  2019        PMID: 31196701     DOI: 10.1016/j.parkreldis.2019.04.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  5 in total

Review 1.  Cerebral Iron Deposition in Neurodegeneration.

Authors:  Petr Dusek; Tim Hofer; Jan Alexander; Per M Roos; Jan O Aaseth
Journal:  Biomolecules       Date:  2022-05-17

2.  Clinical Characterization and Founder Effect Analysis in Chinese Patients with Phospholipase A2-Associated Neurodegeneration.

Authors:  Hao-Ling Cheng; Yi-Jun Chen; Yan-Yan Xue; Zhi-Ying Wu; Hong-Fu Li; Ning Wang
Journal:  Brain Sci       Date:  2022-04-19

3.  Novel PLA2G6 Pathogenic Variants in Chinese Patients With PLA2G6-Associated Neurodegeneration.

Authors:  Yalan Wan; Yanyan Jiang; Zhiying Xie; Chen Ling; Kang Du; Ran Li; Yun Yuan; Zhaoxia Wang; Wei Sun; Haiqiang Jin
Journal:  Front Neurol       Date:  2022-07-13       Impact factor: 4.086

4.  New Insights of Phospholipase A2 Associated Neurodegeneration Phenotype Based on the Long-Term Follow-Up of a Large Hungarian Family.

Authors:  Renata Toth-Bencsik; Peter Balicza; Edina Timea Varga; Andras Lengyel; Gabor Rudas; Aniko Gal; Maria Judit Molnar
Journal:  Front Genet       Date:  2021-06-08       Impact factor: 4.599

5.  Novel deep intronic mutation in PLA2G6 causing early-onset Parkinson's disease with brain iron accumulation through pseudo-exon activation.

Authors:  Ivano Di Meo; Valeria Tiranti; Chiara Cavestro; Celeste Panteghini; Chiara Reale; Alessia Nasca; Silvia Fenu; Ettore Salsano; Luisa Chiapparini; Barbara Garavaglia; Davide Pareyson
Journal:  Neurogenetics       Date:  2021-08-13       Impact factor: 2.660

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.